ScholarIQanswers from OpenAlex
Asklepios Fachkliniken München-Gauting
InstitutionResearch output, impact & collaborations
Asklepios Fachkliniken München-Gauting is a institution indexed in ScholarIQ from OpenAlex.
What is known about Asklepios Fachkliniken München-Gauting?
ScholarIQrecord summary
Asklepios Fachkliniken München-Gauting is a research organisation in Gauting, DE. OpenAlex records 2,060 works and 142,502 citations for it. 486 researchers list it as their most recent affiliation.
How many works does Asklepios Fachkliniken München-Gauting have?
ScholarIQindexed works
Asklepios Fachkliniken München-Gauting has 2,060 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Asklepios Fachkliniken München-Gauting have?
ScholarIQcitation count
Asklepios Fachkliniken München-Gauting has 142,502 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Asklepios Fachkliniken München-Gauting?
ScholarIQresearcher count
Asklepios Fachkliniken München-Gauting has 486 researchers in the ScholarIQ index.
What is the average h-index at Asklepios Fachkliniken München-Gauting?
ScholarIQavg h-index
Asklepios Fachkliniken München-Gauting has an average h-index of 67 in OpenAlex.
What is the ROR of Asklepios Fachkliniken München-Gauting?
ScholarIQror
The ROR for Asklepios Fachkliniken München-Gauting is on the source record.
What is the OpenAlex record for Asklepios Fachkliniken München-Gauting?
ScholarIQopenalex
The OpenAlex for Asklepios Fachkliniken München-Gauting is on the source record.
Who are the most-cited researchers behind Asklepios Fachkliniken München-Gauting?
ScholarIQtop researchers by citations
What are the most-cited papers on Asklepios Fachkliniken München-Gauting?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Nasser H. Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo de Marinis, Joachim von Pawel, U. Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Müller, Hong-Liang Lim, Christopher E. Desch, Klára Szondy, Radj Gervais, Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, A. Vergnenègre, Carlos H. Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andrić, Sarayut Lucien Geater, Mustafa Özgüroğlu, Wei Zou, Alan Sandler, Ida Enquist, Kimberly M. Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Mark L. McCleland, Simonetta Mocci, Jacek Jassem, David R. Spigel
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
How much of the research on Asklepios Fachkliniken München-Gauting is open access?
ScholarIQopen access share
91%OPEN ACCESS